指南与共识其他结缔组织病自身炎症与 IgG4 相关病

EULAR/PRES关于儿童自身免疫炎症性风湿病患者疫苗接种的建议:2021年更新

EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021.
指南 / 共识 · Ann Rheum Dis · 2022-06-20

该建议由EULAR标准操作流程制定,针对儿童自身免疫炎症性风湿病(pedAIIRD)患者提出6条总体原则和7条推荐。核心内容包括:应遵循国家免疫规划并每年由专科医生评估;免疫抑制治疗前接种疫苗但必要治疗不应推迟;非活疫苗可安全用于免疫抑制患者;活疫苗在免疫抑制患者中应避免,但特定条件下可接种麻腮风加强针和水痘带状疱疹病毒疫苗;免疫抑制患者应强烈考虑接种非活季节性流感疫苗。

要点

  • 应遵循国家免疫规划并每年由治疗专科医生评估。
  • 免疫抑制治疗前接种疫苗但必要治疗不应推迟。
  • 非活疫苗可安全用于免疫抑制的pedAIIRD患者。

核心结论

  • 该建议旨在帮助儿科医生、儿童风湿科医生、国家免疫机构、全科医生、患者和国家风湿病学会在免疫受损的pedAIIRD患者中实现安全有效的疫苗接种和最佳感染预防。

研究设计与样本

  • 采用EULAR标准操作流程制定,成立两个国际专家委员会分别更新儿童和成人AIIRD患者的疫苗接种建议,经系统文献综述后分别制定儿童和成人推荐。
  • 针对pedAIIRD制定了6条总体原则和7条推荐,并提供证据等级、推荐强度和特别工作组同意水平。

主要发现

  • 应遵循国家免疫规划并每年由治疗专科医生评估。
  • 如有可能,疫苗接种应在免疫抑制药物之前进行,但必要治疗不应推迟。
  • 非活疫苗可安全用于免疫抑制的pedAIIRD患者。
  • 接受免疫抑制治疗的患者接种疫苗后血清保护主要得以保留,但大剂量糖皮质激素和B细胞清除治疗除外。
  • 免疫抑制患者应避免接种活疫苗,但在特定条件下可安全接种麻腮风加强针和水痘带状疱疹病毒疫苗。

关键数值与推荐

  • 6条总体原则和7条推荐,每条均提供证据等级、推荐强度和特别工作组同意水平。
  • 免疫抑制患者应避免接种活疫苗;特定条件下可安全接种麻腮风加强针和水痘带状疱疹病毒疫苗。
  • 除国家免疫规划外,免疫抑制的pedAIIRD患者应强烈考虑接种非活季节性流感疫苗。

临床怎么用

  • 应遵循国家免疫规划并每年由治疗专科医生评估。
  • 如有可能,疫苗接种应在免疫抑制药物之前进行,但必要治疗不应推迟。
  • 非活疫苗可安全用于免疫抑制的pedAIIRD患者。
  • 免疫抑制患者应避免接种活疫苗,但特定条件下可安全接种麻腮风加强针和水痘带状疱疹病毒疫苗。
  • 除国家免疫规划外,免疫抑制的pedAIIRD患者应强烈考虑接种非活季节性流感疫苗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recent insights supporting the safety of live-attenuated vaccines and novel studies on the immunogenicity of vaccinations in the era of biological disease-modifying antirheumatic drugs in paediatric patients with autoimmune/inflammatory rheumatic diseases (pedAIIRD) necessitated updating the EULAR recommendations. METHODS: Recommendations were developed using the EULAR standard operating procedures. Two international expert committees were formed to update the vaccination recommendations for both paediatric and adult patients with AIIRD. After a systematic literature review, separate recommendations were formulated for paediatric and adult patients. For pedAIIRD, six overarching principles and seven recommendations were formulated and provided with the level of evidence, strength of recommendation and Task Force level of agreement. RESULTS: In general, the National Immunisation Programmes (NIP) should be followed and assessed yearly by the treating specialist. If possible, vaccinations should be administered prior to immunosuppressive drugs, but necessary treatment should never be postponed. Non-live vaccines can be safely given to immunosuppressed pedAIIRD patients. Mainly, seroprotection is preserved in patients receiving vaccinations on immunosuppression, except for high-dose glucocorticoids and B-cell depleting therapies. Live-attenuated vaccines should be avoided in immunosuppressed patients. However, it is safe to administer the measles-mumps-rubella booster and varicella zoster virus vaccine to immunosuppressed patients under specific conditions. In addition to the NIP, the non-live seasonal influenza vaccination should be strongly considered for immunosuppressed pedAIIRD patients. CONCLUSIONS: These recommendations are intended for paediatricians, paediatric rheumatologists, national immunisation agencies, general practitioners, patients and national rheumatology societies to attain safe and effective vaccination and optimal infection prevention in immunocompromised pedAIIRD patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2022. PMID: 35725297. doi:10.1136/annrheumdis-2022-222574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。